NCT03248479 2025-01-17
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Gilead Sciences
Phase 1 Terminated
Clinical Trials
8 trialsNCT06532344 2024-11-14
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT06540261 2024-09-19
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT03558139 2024-04-01
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Gilead Sciences
Phase 1 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT03922477 2022-02-21
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Hoffmann-La Roche
Phase 1 Terminated
NCT02678338 2019-02-21
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Gilead Sciences
Phase 1 Completed
NCT02216409 2019-02-05
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Gilead Sciences
Phase 1 Completed